



Review

The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis

Tannaz Jamialahmadi, Mitra Abbasifard, Željko Reiner, Manfredi Rizzo, Ali H. Eid and Amirhossein Sahebkar

Topic

Biomarkers in Cardiovascular Disease - Chances and Risks

Edited by

Prof. Dr. Tomasz Zieliński and Dr. Anna Konopka





Review

The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis

Tannaz Jamialahmadi ^{1,2}, Mitra Abbasifard ^{3,4}, Željko Reiner ⁵, Manfredi Rizzo ⁶ , Ali H. Eid ⁷
and Amirhossein Sahebkar ^{8,9,*}

- ¹ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran
 - ² Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran
 - ³ Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan 7717933777, Iran
 - ⁴ Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan 7717933777, Iran
 - ⁵ Department of Internal Medicine, University Hospital Center Zagreb, 10000 Zagreb, Croatia
 - ⁶ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, 90133 Palermo, Italy
 - ⁷ Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
 - ⁸ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran
 - ⁹ Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran
- * Correspondence: amir_saheb2000@yahoo.com or sahebkar@mums.ac.ir



Citation: Jamialahmadi, T.; Abbasifard, M.; Reiner, Ž.; Rizzo, M.; Eid, A.H.; Sahebkar, A. The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis. *J. Clin. Med.* **2022**, *11*, 5251. <https://doi.org/10.3390/jcm11175251>

Academic Editors: Tomasz Zielinski and Anna Konopka

Received: 27 July 2022

Accepted: 31 August 2022

Published: 5 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Background: Statins are the most widely used drugs for decreasing elevated serum LDL-cholesterol (LDL-C) and thus for the prevention of atherosclerotic cardiovascular disease (ASCVD), but they have also some pleiotropic effects, including anti-inflammatory properties. Atherosclerosis is a low-grade inflammatory disease, and elevated ferritin is considered to be one of the markers of inflammation. Since the results of studies on the effects of statins on serum ferritin levels are conflicting, this meta-analysis was performed. Methods: A literature search was performed using major electronic databases (MEDLINE/PubMed, Scopus, Embase, and ISI Web of Science) from inception up to 5 March 2022 to find studies evaluating the effect of different statins on serum ferritin levels. The effect size was determined using weighted mean differences (WMDs) and the corresponding 95% confidence intervals (CIs). Results: The meta-analysis of nine studies (1611 patients) analyzing the effects of statins on serum ferritin levels that were included showed a significant decrease in circulating ferritin levels caused by statins. The results did not suggest any significant association between the changes in concentrations of serum ferritin and the duration of treatment with statins. Conclusions: Statin therapy decreases the circulating concentrations of ferritin, which might be beneficial for the prevention and/or progression of ASCVD. This effect might be explained by the anti-inflammatory effects and maybe some other pleiotropic effects of statins and not by their lipid-lowering effects.

Keywords: acute-phase response; lipid-lowering therapy; inflammation; iron; statins; cardiovascular diseases

1. Introduction

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme crucial for the synthesis of cholesterol in cells, particularly hepatocytes. Therefore, statins lower blood cholesterol in two ways: they reduce LDL cholesterol (LDL-C) synthesis in cells by inhibiting HMG-CoA reductase, and they increase the number of receptors for low-density lipoproteins (LDL-R) in cells, thereby removing more cholesterol-rich

LDL particles from the blood, so that the serum LDL-C level is decreased. It is well known that increased LDL-C is the main risk factor for atherosclerotic cardiovascular disease (ASCVD), particularly coronary heart disease, and that the decrease in elevated LDL-C is essential for the prevention of ASCVD [1]. However, statins do not reduce ASCVD morbidity and mortality only by decreasing LDL-C. They have many other anti-atherosclerotic pleiotropic effects independent of their cholesterol-lowering properties, among which anti-inflammatory effects are quite important [2,3]. These unique properties make statins remaining as the most widely prescribed lipid-lowering medications despite several new drugs have that have been introduced to the market [4,5].

It is well known that atherosclerosis is, among others, a low-grade inflammatory disease and that oxidative stress, including iron-induced oxidative stress, plays an important role in inflammatory responses [6]. Acute-phase reaction is a systemic response that typically occurs at the beginning of an inflammatory process [7]. Ferritin and high-sensitivity C Reactive Protein (hs CRP), as positive acute-phase reactants, promote LDL-particle oxidation and cause inflammation in blood vessels.

Ferritin is involved in immune regulation, and it is important to ensure that iron is safely stored and detoxified, preventing the oxidative damage that could be caused by reactions such as Haber–Weiss or Fenton. Ferritin can be found in serum [8], and if elevated, it is considered to be one of the markers of inflammation [9,10]. It can be an enhancer of the inflammatory response increasing the expression of several proinflammatory mediators [11]. A recently published study on a mouse model showed that ferritin could regulate the progress of atherosclerosis by regulating the expression levels of matrix metalloproteinases and interleukins and that silencing ferritin could inhibit the development of atherosclerosis [12]. Some studies showed that ferritin might be an independent risk factor of arterial stiffness [13,14], and arterial stiffness seems to be an independent marker of ASCVD risk [15].

The presence of a statin–iron nexus is proposed based on data indicating that statins modify iron homeostasis and that both statins and reduced ferritin levels appear to be helpful in lowering oxidative stress and related inflammation, resulting in better clinical outcomes [16]. Increased intracellular ferritin greatly contributes to the cytoprotective action of statin-induced heme oxygenase-1(HO-1), which improves iron mobilization and reduces iron levels in atherosclerotic plaques [17]. However, statins may decrease inflammatory as well as noninflammatory mechanisms that cause acute-phase reactions [17,18].

Several studies were published, mostly during the last decade, presenting conflicting results concerning the effects of statins on serum ferritin levels. Therefore, the primary aim of this systematic review and meta-analysis was to find whether statins do have any effect on serum ferritin levels or not. The second goal was to assess the effect of statins on the levels of another marker of inflammation—hs CRP.

2. Methods

2.1. Search Strategy

As described by Jamialahmadi et al. [19], this systematic review and meta-analysis was performed in accordance with the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines [20]. PubMed, Scopus, and Embase, as well as Web of Science, were searched from inception to 5 March 2022, and the following keywords were used in titles and abstracts: (“Hydroxymethylglutaryl-CoA Reductase Inhibitors” OR simvastatin OR rosuvastatin OR atorvastatin OR pravastatin OR pitavastatin OR mevastatin OR fluvastatin OR lovastatin OR cerivastatin) AND (Ferritin OR Ferritins).

2.2. Study Selection

Only studies on humans were included, if they were based on the following inclusion criteria: (i) observational studies assessing the effect of statins on ferritin level, regardless of having a control group or not, and (ii) studies with adequate information at baseline and

at the end of the study in each group. Exclusion criteria were: (i) lack of sufficient data at baseline or follow-up.

2.3. Data Extraction

After the removal of duplicate studies, two independent and blinded authors (T.J. and M.A.) reviewed and screened the titles and abstracts of the eligible studies. Any disagreements were resolved via discussion and consensus. After reviewing the full report of the studies, the following data were abstracted: the name of the first author, the year of publication, the study design, the type and dose of statins, and the duration of follow-up, as well as patient characteristics.

2.4. Quality Assessment

The Newcastle–Ottawa Scale (NOS) was applied to evaluate the two cohort studies [21]. Four studies were evaluated using the Risk of Bias in Nonrandomized Studies—on Interventions (ROBINS-I) tool [22]. In addition, Cochrane Collaboration’s tool was used to assess the risk of bias in three randomized studies [23].

2.5. Quantitative Data Synthesis

According to a previous study by Jamialahmadi et al. [19], Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ, USA) [24] was used to perform the meta-analysis. For each outcome, sample sizes, means, and standard deviations were obtained to calculate the weighted mean differences (WMDs). The effect size was calculated as: (Difference between measured before and after follow-up in the treatment group) – (Difference between measured before and after follow-up in the control group). A random-effects model and the generic inverse-variance weighting method were used to compensate for the heterogeneity of the studies in terms of study design, treatment duration, and the characteristics of the studied populations [20]. In the case of median and range (or 95% confidence interval (CI)), mean and standard deviation were estimated using the method by Hozo et al. [25]. To evaluate the influence of each study on the overall effect size, a sensitivity analysis was performed using the leave-one-out method (i.e., removing one study each time and repeating the analysis) [26,27].

2.6. Meta-Regression

As already described in our previous study [19], the potential confounder of the treatment duration of statin treatment was entered into a random-effects meta-regression model to explore their possible interaction with the estimated effect size.

2.7. Publication Bias

The presence of publication bias was assessed using funnel plot, Begg’s rank correlation, and Egger’s weighted regression tests in the meta-analysis. When funnel plot asymmetry was seen, potentially missing studies were imputed using the “trim and fill” method. When there was evidence of significant results, the number of potentially missing studies required to make the *p*-value non-significant was estimated using the “fail-safe *N*” method as another marker of publication bias [28].

3. Results

Among the 72 published studies identified by performing a systematic database search, 46 were directly related to the topic of this study after the exclusion of duplicates. However, 37 studies were excluded after careful evaluation (5 were review articles, 22 were irrelevant studies, 3 were excluded because of insufficient data, and 7 were animal studies). Therefore, nine observational studies were included in the systematic review and meta-analysis (Table 1). The study selection process is shown in Figure 1.

Table 1. Characteristics of studies in which circulating concentrations of serum ferritin were measured.

Study, Year	Study Design	Follow-Up	Treatment	Control	Clinical Outcome	Patients	No. of Patients
Sirken et al., 2003 [29]	retrospective study	mean of 4.7 months	statin therapy	non-statin therapy	significant decrease in serum ferritin level	dialysis patients	19
Dornbrook-Lavender et al., 2005 [30]	randomized, parallel-group substudy	8 months	A at 10 mg/day	no statins	no significant changes in serum ferritin level	hemodialysis patients	13
Ukinc et al., 2009 [31]	open-label, randomized study	12 months	A at 10 to 20 mg/day	-	significant decrease in serum ferritin level	patients with type 2 diabetes	50
			S at 10 to 20 mg/day	-	significant decrease in serum ferritin level		
Tsouchnikas et al., 2009 [32]	nonrandomized clinical trial	9 months	A at 20 to 40 mg/day	-	no significant changes in serum ferritin level	hemodialysis patients with low-density lipoprotein cholesterol (LDL) >32.58 mmol/L	25
Li et al., 2010 [33]	nonrandomized clinical trial	2 months	S at 20 mg/day	control	no significant changes in serum ferritin level	hemodialysis patients	26
Kimura et al., 2010 [34]	nonrandomized clinical trial	12 months	A at 10 mg/day	-	significant decrease in serum ferritin level	NASH patients with dyslipidemia	43
Mehmet KOC et al., 2011 [35]	retrospective study	3 months	statin	statin nonusers	no significant changes in serum ferritin level	hemodialysis patients	1363
Hyogo et al., 2012 [36]	nonrandomized clinical trial	12 months	A at 10 mg/day	-	no significant changes in serum ferritin level	NASH patients with dyslipidemia (males)	28
					significant change in serum ferritin level	NASH patients with dyslipidemia (females)	14
Nand et al., 2018 [37]	prospective randomized controlled study	4 months	A at 20 mg/day	control	significant change in serum ferritin level	hemodialysis patients	30

A = atorvastatin. S = simvastatin.




Figure 1. Flow chart of identified publications and those included into the meta-analysis.

3.1. Risk-of-Bias Assessment of Clinical Trials

Two cohort studies met the representativeness of Exposed Cohort, Selection of the Non-Exposed Cohort, Ascertainment of Exposure, Comparability of Cohorts on the Basis of the Design or Analysis, and Assessment of Outcome and lacked the presenting of the outcome of interest at the start of study as well as adequacy of follow-up. Among four nonrandomized studies, one study had a critical bias, and three had serious bias. In addition, Cochrane Collaboration’s tool assessed a risk of bias in three randomized studies. All of the selected publications showed a high risk of bias. The quality of the included publications is assessed in Table 2.


Table 2. Quality of bias assessment of the included publications.

Study	Selection				Comparability		Exposure		
	Representativeness of the Exposed Cohort	Selection of the Non-Exposed Cohort	Ascertainment of Exposure	Demonstration That Outcome of Interest Was Not Present at Start of Study	Comparability of Cohorts on the Basis of the Design or Analysis	Assessment of Outcome	Was Follow-Up Long Enough for Outcomes to Occur?	Adequacy of Follow-Up of Cohorts	
Sirken et al., 2003 [29]	*	*	*	-	*	*	-	-	
Mehmet KOC et al., 2011 [35]	*	*	*	-	*	*	-	-	
	Confounding	Participant Selection	Interventions Classification	Intended Interventions Deviations	Missing Data	Outcome Measurement	Reported Results Classification		
Hyogo et al., 2012 [36]	serious	low	low	low	low	low	low		
Tsouchnikas et al., 2007 [32]	serious	low	low	low	serious	low	low		
Xiang-Yang Li et al., 2010 [33]	low	serious	low	low	serious	low	low		
Kimura et al., 2010 [34]	critical	low	low	low	low	low	low		
	Selection Bias			Performance Bias		Detection Bias	Attrition Bias	Reporting Bias	Other Bias
	Random Sequence Generation	Allocation Concealment							
Dornbrook-Lavender et al., 2005 [30]	high		high	high	high	low	low	low	
Ukinc et al., 2009 [31]	high		high	high	high	low	low	unclear	
Nand et al., 2017 [37]	high		high	high	high	low	low	low	

3.2. Effect of Statins on Circulating Concentrations of Serum Ferritin

The meta-analysis of nine trials including 1611 patients demonstrated a significant decrease in circulating ferritin (WMD, -39.491 ; 95% CI, $-66.56, -12.42$; $p = 0.004$) (Figure 2A). The reduction in circulating ferritin because of statin treatment was robust in the leave-one-out sensitivity analyses (Figure 2B).

A



B




Figure 2. (A) Forest plot displaying standardized mean differences and 95% confidence intervals showing the consequence of statin treatment on serum ferritin level. (B) Leave-one-out sensitivity analyses [26–34].

3.3. Meta-Regression

Random-effects meta-regression was performed to assess the impact of potential confounders on the concentrations of the ferritin-lowering effects of statins. The results did not suggest any significant association between the changes in concentrations of ferritin and treatment duration (coefficient, 4.61; 95% CI, −3.55, 12.78; $p = 0.26$) (Figure 3).





Figure 3. Random-effects meta-regression for evaluating the effect of treatment duration.

3.4. Effect of Statins on Circulating Concentrations of Serum hs_CRP

The meta-analysis of six trials [30–33,35,37] including 1507 patients demonstrated a significant decrease in circulating high-sensitivity CRP (hs_CRP) (SMD, -0.534 ; 95% CI, $-0.950, -0.119$; $p = 0.012$) (Figure 4A). The reduction in circulating hs_CRP because of statin treatment as robust in the leave-one-out sensitivity analyses (Figure 4B).

A



B




Figure 4. (A) Forest plot displaying standardized mean differences and 95% confidence intervals showing the consequence of statin treatment on serum hs_CRP level. (B) Leave-one-out sensitivity analyses [27–34].

3.5. Publication Bias

Given the asymmetric funnel plot, Egger's linear regression test (intercept = -0.26 ; standard error = 0.80 ; 95% CI = $-2.07, 1.55$; $t = 0.32$; $df = 9$; two-tailed $p = 0.75$) and Begg's rank correlation test (Kendall's Tau with continuity correction = 0.145 ; $z = 0.62$; two-tailed p -value = 0.53) suggested no publication biases in the meta-analysis of the effects of statins on the serum level of ferritin. Using the "trim and fill" method, no potentially missing studies were imputed, yielding an adjusted effect size (WMD) of -39.49 (95% CI: $-66.55, -12.42$). The "fail-safe N" test showed that 11 missing studies would be needed to bring the effect size down to a non-significant ($p > 0.05$) value (Figure 5).




Figure 5. Funnel plot detailing publication bias in the publications describing the effect of statin treatment on serum ferritin level.

4. Discussion

The results of this meta-analysis, which included nine studies (1611 patients) analyzing the effects of statins on serum ferritin levels, showed a significant decrease in circulating ferritin levels caused by treatment with statins. The results did not suggest any significant association between the changes in concentrations of serum ferritin and the duration of treatment with statins. In addition, hs-CRP levels significantly decreased after treatment with statins. This effect might be explained by the anti-inflammatory pleiotropic effects of statins and not their lipid-lowering effects.

It has to be stressed that a recent population-based cohort study on 242,084 participants who were followed for more than 8 years showed that high levels of serum ferritin were not associated with an increased risk of acute CHD [38]. The negative results were explained by the overall lower prevalence of CHD in the analyzed population compared with other studies. These results are similar to an earlier study on black population ($n = 4659$) without known atherosclerotic CHD suggesting that higher serum ferritin levels were not associated with an increased risk of atherosclerotic CHD events or stroke [39]. This study did not account for comorbidities such as chronic inflammatory conditions, which can affect blood ferritin levels and were associated with CHD in several earlier studies. Furthermore, because they only included black population, our findings may not be generalizable to other ethnicities or the general public. These two reasons were suggested as controversies in previous studies.

On the other hand, the FeAST trial, a clinical trial of iron reduction by graded phlebotomy, showed that iron reduction caused a significant age-related improvement in ASCVD outcomes. A small substudy of this trial lasting six years that used phlebotomy showed that statin treatment was associated with significantly lower ferritin levels [6]. Another substudy of the FeAST trial also showed results similar to those obtained by our meta-analysis, indicating that statins increased the high-density lipoprotein cholesterol (HDL-C)-to-LDL-C ratios and reduced ferritin levels via noninteracting mechanisms [16,40]. One of the proposed mechanisms connecting statins and iron metabolism, including ferritin levels, is that in secondary prevention, statins may in part stabilize atherosclerotic plaques by inducing intralésional heme oxygenase-1 (HO-1). HO-1 is the rate-limiting enzyme involved in heme catabolism [17] that facilitates iron mobilization and decreases the iron levels in the atherosclerotic plaque [18].

This study has some limitations. A major limitation was the relatively small number of the included studies and the relatively small number of participants in some of the included studies. Another possible limitation might have been the lack of simultaneous measurements and analysis of other markers of inflammation such as interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor (TNF)-alpha.

5. Conclusions

This meta-analysis showed that statin therapy caused a significant decrease in circulating ferritin levels. The results did not suggest any significant association between the changes in concentrations of serum ferritin and the duration of treatment with statins. In addition, statin therapy reduced hs-CRP levels in circulation. This effect might be explained by the anti-inflammatory and maybe some other pleiotropic effects of statins and not their lipid-lowering effects.

Author Contributions: Conceptualization, T.J., M.A., Ž.R., M.R., A.H.E. and A.S.; Data curation, T.J., Ž.R. and A.H.E.; Formal analysis, M.A.; Investigation, T.J. and A.S.; Methodology, M.R. and A.S.; Supervision, M.A., Ž.R. and M.R.; Validation, T.J.; Writing—original draft, M.A., Ž.R., A.H.E. and A.S.; Writing—review & editing, Ž.R., M.R., A.H.E. and A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Reiner, Ž. Statins in the primary prevention of cardiovascular disease. *Nat. Rev. Cardiol.* **2013**, *10*, 453–464. [[CrossRef](#)]
2. Mk, J.; Ridker, P.M. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. *Nat. Rev. Drug Discov.* **2005**, *4*, 977–987.
3. Shakour, N.; Ruscica, M.; Hadizadeh, F.; Cirtori, C.; Banach, M.; Jamialahmadi, T.; Saheb-kar, A. Statins and C-reactive protein: In silico evidence on direct interaction. *Arch. Med. Sci.* **2020**, *16*, 1432–1439. [[CrossRef](#)] [[PubMed](#)]
4. Sahebkar, A.; Watts, G.F. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. *Clin. Ther.* **2013**, *35*, 1082–1098. [[CrossRef](#)] [[PubMed](#)]
5. Sahebkar, A.; Watts, G.F. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect? *Cardiovasc. Drugs Ther.* **2013**, *27*, 559–567. [[CrossRef](#)] [[PubMed](#)]
6. DePalma, R.G.; Hayes, V.W.; Chow, B.K.; Shamayeva, G.; May, P.E.; Zacharski, L.R. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: A substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. *J. Vasc. Surg.* **2010**, *51*, 1498–1503. [[CrossRef](#)]
7. Ahmed, M.S.; Jadhav, A.B.; Hassan, A.; Meng, Q.H. Acute phase reactants as novel predictors of cardiovascular disease. *ISRN Inflamm.* **2012**, *2012*, 953461. [[CrossRef](#)] [[PubMed](#)]
8. Wang, W.; Knovich, M.A.; Coffman, L.G.; Torti, F.M.; Torti, S.V. Serum ferritin: Past, present and future. *Biochim. Biophys. Acta (BBA)-Gen. Subj.* **2010**, *1800*, 760–769. [[CrossRef](#)] [[PubMed](#)]

9. Recalcati, S.; Invernizzi, P.; Arosio, P.; Cairo, G. New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. *J. Autoimmun.* **2008**, *30*, 84–89. [[CrossRef](#)] [[PubMed](#)]
10. Knovich, M.A.; Storey, J.A.; Coffman, L.G.; Torti, S.V.; Torti, F.M. Ferritin for the clinician. *Blood Rev.* **2009**, *23*, 95–104. [[CrossRef](#)]
11. Ruddell, R.G.; Hoang-Le, D.; Barwood, J.M.; Rutherford, P.S.; Piva, T.J.; Watters, D.J.; Santambrogio, P.; Arosio, P.; Ramm, G.A. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. *Hepatology* **2009**, *49*, 887–900. [[CrossRef](#)]
12. Zheng, M.; Li, L.; Liu, Y.; Liang, Y.; Qi, X. Silencing ferritin alleviates atherosclerosis in mice via regulating the expression levels of matrix metalloproteinases and interleukins. *Acta Biochim. Pol.* **2021**, *68*, 705–710. [[CrossRef](#)]
13. Sciacqua, A.; Ventura, E.; Tripepi, G.; Cassano, V.; D'Arrigo, G.; Roumeliotis, S.; Maio, R.; Miceli, S.; Perticone, M.; Andreozzi, F.; et al. Ferritin modifies the relationship between inflammation and arterial stiffness in hypertensive patients with different glucose tolerance. *Cardiovasc. Diabetol.* **2020**, *19*, 1–10. [[CrossRef](#)]
14. Ha, J.Y.; Kim, M.K.; Kang, S.; Nam, J.S.; Ahn, C.W.; Kim, K.R.; Park, J.S. Serum ferritin levels are associated with arterial stiffness in healthy Korean adults. *Vasc. Med.* **2016**, *21*, 325–330. [[CrossRef](#)] [[PubMed](#)]
15. Poredoš, P.; Cífková, R.; Maier, J.A.M.; Nemcsik, J.; Šabovič, M.; Jug, B.; Ježovnik, M.K.; Schernthaner, G.H.; Antignani, P.L.; Catalano, M.; et al. Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events? *Atherosclerosis* **2022**, *348*, 25–35.
16. Zacharski, L.R.; DePalma, R.G.; Shamayeva, G.; Chow, B.K. The statin–iron nexus: Anti-inflammatory intervention for arterial disease prevention. *Am. J. Public Health* **2013**, *103*, e105–e112. [[CrossRef](#)]
17. Ali, F.; Hamdulay, S.S.; Kinderlerer, A.R.; Boyle, J.J.; Lidington, E.A.; Yamaguchi, T.; Soares, M.P.; Haskard, D.O.; Randi, A.M.; Mason, J.C. Statin-mediated cytoprotection of human vascular endothelial cells: A role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. *J. Thromb. Haemost.* **2007**, *5*, 2537–2546. [[CrossRef](#)]
18. Sullivan, J.L. Iron in arterial plaque: A modifiable risk factor for atherosclerosis. *Biochim. Biophys. Acta (BBA)-Gen. Subj.* **2009**, *1790*, 718–723. [[CrossRef](#)]
19. Jamialahmadi, T.; Baratzadeh, F.; Reiner, Ž.; Simental-Mendía, L.E.; Xu, S.; Susekov, A.V.; Santos, R.D.; Sahebkar, A. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Mediat. Inflamm.* **2021**, *2021*, 9661752. [[CrossRef](#)]
20. Sutton, A.J.; Abrams, K.R.; Jones, D.R.; Jones, D.R.; Sheldon, T.A.; Song, F. *Methods for Meta-Analysis in Medical Research*; Wiley: Chichester, UK, 2000.
21. Wells, G.; Shea, B.; O'Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P.; Ga, S.W.; Zello, G. *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses*; Oxford: Oxford, UK, 2000.
22. Sterne, J.A.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* **2016**, *355*, i4919. [[CrossRef](#)]
23. Higgins, J.P.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. *Cochrane Handbook for Systematic Reviews of Interventions*; John Wiley & Sons: Hoboken, NJ, USA, 2019.
24. Borenstein, M.; Hedges, L.; Higgins, J.; Rothstein, H. *Comprehensive Meta-Analysis*, 2nd ed.; Biostat: Englewood, NJ, USA, 2005.
25. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med. Res. Methodol.* **2005**, *5*, 1–10. [[CrossRef](#)] [[PubMed](#)]
26. Sahebkar, A.; Serban, C.; Ursoniu, S.; Wong, N.D.; Muntner, P.; Graham, I.M.; Mikhailidis, D.P.; Rizzo, M.; Rysz, J.; Sperling, L.S.; et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—Results from a systematic review and meta-analysis of randomized controlled trials. *Int. J. Cardiol.* **2015**, *189*, 47–55. [[CrossRef](#)] [[PubMed](#)]
27. Banach, M.; Serban, C.; Ursoniu, S.; Rysz, J.; Muntner, P.; Toth, P.P.; Jones, S.R.; Rizzo, M.; Glasser, S.P.; Watts, G.F.; et al. Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. *Pharmacol. Res.* **2015**, *99*, 329–336. [[CrossRef](#)] [[PubMed](#)]
28. Duval, S.; Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* **2000**, *56*, 455–463. [[CrossRef](#)]
29. Sirken, G.; Kung, S.-C.; Raja, R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. *Asaio J.* **2003**, *49*, 422–425. [[CrossRef](#)]
30. Dornbrook-Lavender, K.A.; Joy, M.S.; Denu-Ciocca, C.J.; Chin, H.; Hogan, S.L.; Pieper, J.A. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. *Pharmacother. J. Hum. Pharmacol. Drug Ther.* **2005**, *25*, 335–344. [[CrossRef](#)]
31. Ukinc, K.; Ersoz, H.O.; Erem, C.; Hacihasanoglu, A.B.; Karti, S.S. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. *Endocrine* **2009**, *35*, 380–388. [[CrossRef](#)]
32. Tsouchnikas, I.; Dounousi, E.; Papakonstantinou, S.; Ioannou, K.; Kelesidis, A.; Kotzadamis, N.; Xanthopoulou, K.; Tsakiris, D. Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients. *Nephrology* **2009**, *14*, 560–564. [[CrossRef](#)]
33. Li, X.Y.; Chang, J.P.; Su, Z.W.; Li, J.H.; Peng, B.S.; Zhu, S.L.; Cai, A.J.; Zhang, J.; Jiang, Y. How Does Short-Term Low-Dose Simvastatin Influence Serum Prohepcidin Levels in Patients With End-Stage Renal Disease? A Pilot Study. *Ther. Apher. Dial.* **2010**, *14*, 308–314. [[CrossRef](#)]

34. Kimura, Y.; Hyogo, H.; Yamagishi, S.I.; Takeuchi, M.; Ishitobi, T.; Nabeshima, Y.; Arihiro, K.; Chayama, K. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: Clinical usefulness of AGEs as a biomarker for the attenuation of NASH. *J. Gastroenterol.* **2010**, *45*, 750–757. [[CrossRef](#)]
35. Koc, M.; Dogan, C.; Arinsoy, T.; Tonbul, Z.; Ayli, D.; Cirit, M.; Sever, M.S.; Yilmaz, M.E.; Unsal, A.; Suleymanlar, G.; et al. Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. *Hemodial. Int.* **2011**, *15*, 366–373. [[CrossRef](#)]
36. Hyogo, H.; Yamagishi S-i Maeda, S.; Kimura, Y.; Ishitobi, T.; Chayama, K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- α -lowering property. *Dig. Liver Dis.* **2012**, *44*, 492–496. [[CrossRef](#)]
37. Nand, N.; Mittal, A. Evaluation of Effect of Statins on Erythropoietin Resistance in Patients of Chronic Kidney Disease on Maintenance Haemodialysis. *J. Assoc. Physicians India* **2018**, *66*, 29–32.
38. Reyes, C.; Pons, N.A.; Reñones, C.R.; Gallisà, J.B.; Val, V.A.; Tebé, C.; Mateo, G.F. Association between serum ferritin and acute coronary heart disease: A population-based cohort study. *Atherosclerosis* **2020**, *293*, 69–74. [[CrossRef](#)]
39. Egbuche, O.; Millard, H.R.; Renelus, B.; Maihemuti, A.; Musani, S.K.; Fox, E.R.; Liu, J.; Taylor, H.A.; Bidulescu, A. Serum ferritin levels in blacks without known cardiovascular disease (from the Jackson heart study). *Am. J. Cardiol.* **2017**, *120*, 1533–1540. [[CrossRef](#)]
40. Zacharski, L.R.; Chow, B.K.; Howes, P.S.; Shamayeva, G.; Baron, J.A.; Dalman, R.L.; Malenka, D.J.; Ozaki, C.K.; Lavori, P.W. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: A randomized controlled trial. *JAMA* **2007**, *297*, 603–610. [[CrossRef](#)]